Link to OncoLink

Canine Multicentric Subcutaneous Hemangiosarcoma (HSA)

Ultima Vez Modificado: 4 de diciembre del 2003

Question

Dear OncoLink "Ask The Experts,"
My dog was diagnosed with hemangiosarcoma. She also has a history of mast cell tumor grade II. She is a 13 year old mixed shepherd. Her tail was amputated, because the tumor was on the base. She also had 4 superficial tumors removed. They all came back as Multicentric Subcutaneous Hemangiosarcoma. The tail mass came back as mast cell tumor, but the biopsy showed to be HSA. What protocols should I consider? 

Answer

Lili Duda, VMD, Section Editor of the OncoLink Veterinary Oncology Menu, responds:

The dog described has multicentric subcutaneous hemangiosarcoma (HSA), which is one of the possible presentations in dogs. This is still considered a high-grade hemangiosarcoma with the same clinical course and treatment recommendations as for visceral (e.g. splenic) HSA. The current treatment options are Adriamycin/Cytoxan every three weeks, although single-agent Adriamycin every two weeks is also being used with roughly comparable results. Chemotherapy can delay the onset of metastasis to lungs/liver/spleen and elsewhere, but unfortunately prognosis is still grim.

As far as mast cells being found on fine-needle aspirate of the tail mass, which was ultimately diagnosed as HSA – it is very difficult to comment without seeing the cytology report of the fine-needle aspirate. However, mast cells are a normal component of an inflammatory cell infiltrate, and small numbers are often present on aspirates of inflamed tissues. Mast cells can sometimes constitute a large percentage of the inflammatory cells. In addition, hemangiosarcomas can be difficult to diagnose on cytology, as the malignant cells tend not to exfoliate very well, and the aspirates are often very blood-diluted due to the vascular nature of these tumors.

OncoLink I wish u knew...

3D mammography, also known as digital tomosynthesis, is a new technology aimed at having better detection of abnormalities and fewer false positives. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS